Background:

Gestonorone Capronate is a progestin for the treatment of benign prostatic hypertrophy and endometrial cancer.

The administration of gestonorone capronate impedes testosterone reduction. The oxydation pathway remains uninfluenced. This inhibition of the formation of 5α-reduction products is present at the lowest dose of gestonorone capronate and is augmented progressively with increasing gestonorone capronate concentration[1].

[1]. Orestano F, et al. Mode of action of progesterone, gestonorone capronate (Depostat) and cyproterone acetate (Androcur) on the metabolism of testosterone in human prostatic adenoma: in vitro and in vivo investigations. J Steroid Biochem. 1975 Jun;6(6):845-51.